# A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

> **NCT00373113** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 482 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Sunitinib malate

## Key facts

- **NCT ID:** NCT00373113
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2009-10
- **Final completion:** 2011-06
- **Target enrollment:** 482 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373113, "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00373113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*